Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | PRKCA | P17252 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390485 | 0.93 | CYP1A2 (0.49) | CYP1A2PRKCACA1CA9PPARG | |
| SCHEMBL14615638 | 0.80 | CYP1A2 (0.36) | CYP1A2 | |
| SCHEMBL4392084 | 0.78 | — | — | |
| SCHEMBL14615633 | 0.72 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL6009850 | 0.71 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL21047782 | 0.70 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL21047750 | 0.70 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL7059195 | 0.70 | CYP1A2 (1.00) | CYP1A2PRKCAPPARG | |
| SCHEMBL21047885 | 0.70 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL21047731 | 0.70 | CYP1A2 (0.39) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090305239-A1 | Methods and compositions for determing a level of biologically active serum paraoxonase | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-12-10 | — | — | US | disclosed |
| US-20090305239-A1 | Methods and compositions for determing a level of biologically active serum paraoxonase | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-12-10 | — | — | US | disclosed |
| US-20090305239-A1 | Methods and compositions for determing a level of biologically active serum paraoxonase | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2009-12-10 | — | — | US | disclosed |
| EP-1915457-A2 | METHODS AND COMPOSITIONS FOR DETERMINING A LEVEL OF BIOLOGICALLY ACTIVE SERUM PARAOXONASE | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007020632-A2 | METHODS AND COMPOSITIONS FOR DETERMINING A LEVEL OF BIOLOGICALLY ACTIVE SERUM PARAOXONASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305239-A1 | Methods and compositions for determing a level of biologically active serum paraoxonase | PON1, LPO, PNLIP | CYP1A2 193/4885PRKCA 2957/4885CA1 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.